Physicians who own their own practices should feel honored! They are the focus of an ongoing tug-of-war between the biggest stakeholders in the healthcare industry. The prize in this contest is the independent physician practice. The winner of the contest gains a powerful advantage in payer/provider network negotiations, as well as control over the gateway to the healthcare system.
For several years now, large integrated hospital systems have become larger through acquisition of physician practices. This is not a new dynamic, and the rationale hasn’t changed; controlling more healthcare services results in local market . This dominance leads to a stronger position as the hospital system negotiates for higher payments from insurance companies.
In response, payers have been hiring and purchasing their own healthcare providers. Not only is UHC the largest commercial insurer in the country, it is also the largest employer of healthcare providers. Employing providers offers two primary advantages to a payer:
They can better control the initial prescribing decision and referral patterns as patients enter the healthcare system
This latter scenario is happening in several markets across the country. due to failed negotiations. UHC can take stronger stances against hospital contract demands partially due to the availability of their own organic provider network.
BCBS of Michigan offers a program that helps physicians “optimize their business practices”
BCBS of North Carolina offers a program “to make sure independent physician practices survive”
IMPACT on Pharma
The three scenarios described above create very different prescribing environments, each impacting the pharmaceutical industry in unique ways:
When the prescriber is owned by a hospital system
They don’t reflect a single payer’s formulary; they represent the merger of many payer formularies. This means each hospital formulary is unique, and is enforced by the system’s Electronic Health Record (EHR), which only offers preferred treatment options to
When the prescriber works for a payer
These prescribers are strongly encouraged to follow their employer’s formulary. As you would expect, formulary adherence rates are very high in this environment
When a practice is independent
Prescriptions in this environment have very little financial impact on independent physicians. They write a prescription (generally following patient-specific coverage restrictions), and a pharmacy worries about the rest.
Look for the influence
Selling in these different environments requires different strategies and tactics. For example, if hospital systems win the tug of war for more physician practices, then sales efforts should focus on decision makers at the top of the system’s decision tree. If payers win, then higher rebates may be worth the market share to be gained.
Share Post:
Strengthen Your Customer Connections
Understanding the world prescribers are living in allows for more meaningful customer interactions. MAP Training Programs build your knowledge on marketplace trends impacting providers and the pharmaceutical industry today.
Copay accumulator programs have only one purpose; increase profits for payers. Patients don’t gain an advantage, nor do manufacturers. On top of that, providers face the difficulty of helping patients
The 340B Program remains controversial. Hospitals and other Covered Entities (providers qualified to buy drugs at 340B prices) that benefit from the program describe it as a lifeline that keeps
The Inflation Reduction Act (IRA) passed on August 16th, 2022 brings big changes for the pharmaceutical industry. On August 31st we had a live discussion on the law’s anticipated impact.
September 15, 2022
Keep your finger on the pulse
Subscribe to receive updates on the latest marketplace trends impacting pharma
*required fields
Manufacturers Restricting 340B Sales to Contract Pharmacies